A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
Status:
Terminated
Trial end date:
2021-07-27
Target enrollment:
Participant gender:
Summary
A randomized multi-arm study evaluating the safety and efficacy of palbociclib and
anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer